NASDAQ:ENLV - Enlivex Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.00
  • Forecasted Upside: 266.67 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.00
▼ -0.22 (-2.39%)

This chart shows the closing price for ENLV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enlivex Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENLV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENLV

Analyst Price Target is $33.00
▲ +266.67% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Enlivex Therapeutics in the last 3 months. The average price target is $33.00, with a high forecast of $33.00 and a low forecast of $33.00. The average price target represents a 266.67% upside from the last price of $9.00.

This chart shows the closing price for ENLV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Enlivex Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2021HC WainwrightReiterated RatingBuy$33.00High
3/2/2021HC WainwrightBoost Price TargetPositive ➝ Buy$22.00 ➝ $33.00Medium
10/2/2020HC WainwrightReiterated RatingBuyHigh
9/8/2020HC WainwrightReiterated RatingBuyHigh
7/21/2020HC WainwrightReiterated RatingBuy$22.00Medium
5/8/2020HC WainwrightReiterated RatingBuyLow
3/19/2020HC WainwrightReiterated RatingBuy$22.00High
3/10/2020HC WainwrightBoost Price TargetBuy$20.00 ➝ $22.00Medium
1/9/2020HC WainwrightInitiated CoverageBuy$20.00High
(Data available from 6/24/2016 forward)
Enlivex Therapeutics logo
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.
Read More

Today's Range

Now: $9.00
Low: $8.92
High: $9.30

50 Day Range

MA: $9.87
Low: $8.61
High: $12.10

52 Week Range

Now: $9.00
Low: $4.49
High: $29.40

Volume

41,256 shs

Average Volume

283,293 shs

Market Capitalization

$141.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Enlivex Therapeutics?

The following sell-side analysts have issued stock ratings on Enlivex Therapeutics in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for ENLV.

What is the current price target for Enlivex Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Enlivex Therapeutics in the last year. Their average twelve-month price target is $33.00, suggesting a possible upside of 263.0%. HC Wainwright has the highest price target set, predicting ENLV will reach $33.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $33.00 for Enlivex Therapeutics in the next year.
View the latest price targets for ENLV.

What is the current consensus analyst rating for Enlivex Therapeutics?

Enlivex Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENLV will outperform the market and that investors should add to their positions of Enlivex Therapeutics.
View the latest ratings for ENLV.

What other companies compete with Enlivex Therapeutics?

How do I contact Enlivex Therapeutics' investor relations team?

Enlivex Therapeutics' physical mailing address is 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042. The company's listed phone number is 972-2620-8072 and its investor relations email address is [email protected] The official website for Enlivex Therapeutics is www.enlivex.com.